Johnson & Johnson (JNJ)
J&J's New Growth Powerhouses: Immunology and Neuroscience
J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.
5 Dependable Dividend Stocks to Buy in August
Boring wins in August. While the market chases AI multiples and momentum trades, a quiet cohort of blue-chip dividend compounders continues doing what it has done for decades: raise the payout, return capital, and reward patience.
Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now
Johnson & Johnson has delivered a 28% total return YTD, outperforming SPY and XLV, but now trades at a premium valuation. Despite solid Q2 results and raised FY 2026 guidance, JNJ's stock is deemed fully priced, warranting a reiterated hold rating. Key risks include MedTech growth softness, ongoing litigation, and macro uncertainties, while Pharma momentum drives guidance upgrades.
Why Is Johnson & Johnson (JNJ) Up 4.8% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?
At $261.81, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.
Why PG, JNJ, and KO Could Surprise Investors Next Year
Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market's most reliable dividend payers stand out as durable compounders.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
5 Dividend Stocks Every Boomer Should Own Heading Into Fall
Boomers heading into Fall 2026 are doing what disciplined income investors always do in August: rotating away from summer growth chasers and locking in reliable Q3 and Q4 cash flow.
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript
J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
